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High gastrin releasing peptide receptor (GRPR) expression is associated with numerous cancers including prostate and breast
cancer. The aim of the current study was to develop a 55Co-labeled PET agent based on GRPR antagonist RM26 for visualization
of GRPR-expressing tumors. Labeling with 57Co and 55Co, stability, binding specificity, and in vitro and in vivo characteristics of
57Co-NOTA-PEG2-RM26were studied. NOTA-PEG2-RM26was successfully radiolabeled with
57Co and 55Cowith high yields and
demonstrated high stability.The radiopeptide showed retained binding specificity to GRPR in vitro and in vivo. 57Co-NOTA-PEG2-
RM26 biodistribution in mice was characterized by rapid clearance of radioactivity from blood and normal non-GRPR-expressing
organs and low hepatic uptake. The clearance was predominantly renal with a low degree of radioactivity reabsorption. Tumor-to-
blood ratios were approximately 200 (3 h pi) and 1000 (24 h pi).The favorable biodistribution of cobalt-labeled NOTA-PEG2-RM26
translated into high contrast preclinical PET/CT (using 55Co) and SPECT/CT (using 57Co) images of PC-3 xenografts. The initial
biological results suggest that 55Co-NOTA-PEG2-RM26 is a promising tracer for PET visualization of GRPR-expressing tumors.
1. Introduction
Receptors for small regulatory peptides are often overex-
pressed in human malignant tumors. This observation has
led to a number of studies exploring the opportunity for
clinical application of peptide analogs in tumor diagnosis
and therapy [1]. One promising approach is to target the
gastrin releasing peptide receptor (GRPR) using bombesin
analogs. HighGRPR expressionwas documented in the early,
androgen-dependent stages of prostate cancer (PCa), but not
in the hyperplastic prostate. Therefore GRPR has emerged as
an attractive target in PCa, a notoriously difficult cancer to
diagnose and stage using conventional imaging techniques.
Bombesin (BN) is a 14-amino acid peptide that binds
to GRPR with high affinity. Over the past decade, several
derivatives of bombesin have been investigated in preclinical
and clinical studies. Initially, the consensus was that agonists
were superior to antagonists due to the rapid radioligand
internalization. The high internalization was considered to
be essential for optimal imaging because it provides efficient
intracellular trapping of radiometal labels [2]. However, the
strong physiological action and mitogenicity associated with
BN-based GRPR-agonists [3] and the superior tumor uptake
seen for somatostatin antagonists [4] led to a paradigm
shift towards the use of potent GRPR antagonists in the
development of BN analogs during recent years [5].
Previously, our group reported a high affinity GRPR
antagonist based on RM26 (DPhe-Gln-Trp-Ala-Val-Gly-His-
Sta-Leu-NH2) [6] conjugated to a 1,4,7-triazacyclononane-
N,N󸀠,N󸀠󸀠-triacetic acid (NOTA) chelator via a diethylene
glycol (PEG2) spacer (NOTA-PEG2-RM26). This construct
was initially radiolabeled with 68Ga and 18F [7, 8] for positron
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emission tomography (PET) imaging and 111In [7] for single
photon emission computer tomography (SPECT) imaging.
The 68Ga and 111In-labeled constructs showed favorable
pharmacokinetic properties and high affinity to GRPR. In
an attempt to further improve the biodistribution profile for
potential clinical use, we have also explored the use of dif-
ferent radionuclide-chelator complexes. It is known that the
combination of radionuclide and chelator could have a strong
influence on the targeting properties of radiopeptides [9,
10]. For example, the somatostatin analog [57Co-(dotatoc)]
had the highest reported affinity for somatostatin receptor
subtype 2 (SSTR2) [11]. Our studies on PEG2-RM26 labeled
with 68Ga and 111In using different macrocyclic chelators
demonstrated that charge and structure of the radionuclide-
chelator complex have a strong influence on binding affinity
and liver uptake of the radioconjugates [12, 13].
One interesting finding from our studies was that the
tumor-to-background ratios increased significantly over time
up to 24 h after injection (pi) [7, 13] due to the high uptake and
long retention in tumors in combination with the fast clear-
ance from blood and GRPR-expressing organs, underscoring
the importance of radionuclide half-life in high sensitivity
molecular imaging.These data are in agreement with findings
from the head-to-head evaluation of 55Co- and 68Ga-labeled
GRPR agonist NOTA-AMBA. In this study, 55Co-NOTA-
AMBA provided superior imaging contrast compared to
the 68Ga-labeled counterpart because of the possibility of
performing imaging at 24 h pi. However, both 68Ga- and
55/57Co-labeled NOTA-AMBA had a prolonged retention in
GRPR-expressing tissues, typical for agonists [14]. This issue
might be solved by the use of a high affinity GRPR antagonist.
Thus, the use of a long lived radionuclide for next
day imaging may enable the detection of low abdominal
lymph node involvement, which requires the highest possible
sensitivity and is an ultimate goal in prostate cancer imaging
[15, 16]. Labeling of RM26with a long lived positron-emitting
radionuclide could further increase diagnostic accuracy due
to the inherent high sensitivity and imaging quantitation
capability of PET compared to SPECT. For next day imaging,
a positron-emitting radiometal with a half-life of 10–20 h
would be optimal. Possible PET radionuclides for such
purposes include 64Cu (𝑇1/2 = 12.7 h), 86Y (𝑇1/2 = 14.7 h),
and 55Co (𝑇1/2 = 17.5 h). Among them, 55Co (76% 𝛽+) has
a higher positron abundance compared to 64Cu and a better
ratio between annihilation photons and coemitted gammas
compared to 86Y, providing better image quality [17]. The
17.5 h half-life of 55Co not only allows for delayed imaging
investigations, but also enables shipment to stand-alone PET
scanners.
The goal of this study was to evaluate the tumor targeting
properties of GRPR antagonist NOTA-PEG2-RM26 labeled
with 55Co.
2. Materials and Methods
2.1. Radiochemistry. NOTA-PEG2-RM26 (RM26 = [D-Phe6,
Sta13, Leu14] bombesin [6-14]) was synthesized by standard
manual solid-phase peptide synthesis based on previously
published procedures [7].
57Co cobalt chloride was purchased from PerkinElmer
Sweden (Upplands Va¨sby, Sweden). 55Co was produced in-
house as previously described [18] with an extra purification
step added [19]. Buffers, including 0.2M ammonium acetate,
pH 5.5, and 0.2M citric acid, were produced in-house
from chemicals supplied by Merck (Darmstadt, Germany).
Phosphate buffered saline (PBS), pH 7.5, 0.1Mwas purchased
from the National Veterinary Institute, SVA, Sweden. Buffers
for labeling were purified from free metals contamination by
Chelex 100 resin (Bio-Rad Laboratories, Hercules, CA).
Radiolabeling with 57Co was performed using
3.8–10 nmol (aq. 1 nmol/𝜇L) of NOTA-PEG2-RM26 buffered
with 80 𝜇L ammonium acetate (0.2M, pH 5.5). The mixture
was incubated with 57Co cobalt chloride (10–50MBq) for
30min at 60∘C. For 55Co labeling, 1.3 nmol of NOTA-PEG2-
RM26bufferedwith 80 𝜇L ammoniumacetate (0.2M, pH5.5)
was heated by microwave irradiation for 1min at 850W in a
sealed vial using a conventional microwave oven (Samsung
MW82N-B). To evaluate the labeling stability, 57Co-NOTA-
PEG2-RM26 was incubated in the presence of 1000-fold
molar excess of EDTA disodium salt (Sigma) for 1 h at RT.
Labeling yield, radiochemical purity, and in vitro stability
were analyzed using instant thin-layer chromatography
(ITLC) strips (Agilent Technologies) eluted with citric acid
(0.2M, pH 2.0). In this system, free 57/55Comigrates with the
eluent front (𝑅𝑓 = 1.0) and the radiolabeled construct stays
on the application point (𝑅𝑓 = 0.0). The system was previ-
ously validated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and radio-HPLC [7, 8].
2.2. In Vitro Studies. PC-3 human prostate cancer cells
expressing GRPR were purchased form ATCC via LGC
Promochem. The cells were cultured in RPMI-1640 media
supplemented with 10% fetal calf serum, PEST (penicillin
100 IU/mL, streptomycin 100𝜇g/mL), and 2mML-glutamine
(all from Biochrom AG, Berlin, Germany). This medium
is referred to as complete medium in the text. Trypsin-
EDTA (0.05% trypsin, 0.02% EDTA in buffer; BiochromAG)
was used for cell detachment. All in vitro experiments were
performed in triplicate.
The binding specificity of 57Co-NOTA-PEG2-RM26 was
evaluated using PC-3 cells incubated with 1 nM 57Co-NOTA-
PEG2-RM26 solution for 1 h at 37
∘C. In this experiment one
set of dishes was preincubated for 10min at RT with an
excess (100-fold) of nonlabeled peptide before applying the
radioactivity. After incubation, the cells were washed with
serum-free media and detached with 0.5mL trypsin-EDTA
solution. Radioactivity of cells wasmeasured in an automated
gamma-counter (3-inch NaI(Tl) detector, 2480 WIZARD2,
PerkinElmer) and presented as cell-associated percentage
from added radioactivity.
Cellular processing of the conjugate was evaluated using
PC-3 cells incubated with 1 nM of 57Co-NOTA-PEG2-RM26
at 37∘C, 5% CO2. At predetermined time points (1, 2, 4, 8,
and 24 h after the start of incubation) the medium from 3
dishes was discarded and the cells were washed with ice-cold
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serum-free medium.Themembrane-bound and internalized
radioactivity were collected using the acid wash method
described earlier [7].
The half maximal inhibitory concentration (IC50) was
determined for natCo-NOTA-PEG2-RM26 using the uni-
versal BN radioligand 125I-Tyr4-BBN (Perkin Elmer). For
comparison, an additional experiment was performed in par-
allel for the previously evaluated natIn-NOTA- PEG2-RM26,
under the same experimental conditions [7]. Briefly, cell
monolayerswere incubatedwith 125I-Tyr4-BBN (0.1 pmol) for
5 h at 4∘C in the presence of increasing concentrations of
natCo-loaded and natIn-loaded conjugates (0–1000 nM). After
incubation, the cells were collected and the cell-associated
radioactivity wasmeasured in an automated gamma-counter.
The IC50 values were calculated by nonlinear regression using
GraphPad Prism software (GraphPad Software Inc.).
The binding kinetics were measured in real-time using
LigandTracer Yellow Instruments (Ridgeview Instruments
AB) at room temperature, as described earlier [20]. The
uptake curves were recorded at 0.33 and 6 nM. After mea-
suring the uptake curves, the 57Co-NOTA-PEG2-RM26-
containing medium was replaced by fresh medium and
the dissociation curve was monitored overnight. Data
were collected and evaluated using TracerDrawer software
(Ridgeview Instruments AB).
2.3. In Vivo Studies. The animal experiments were planned
and performed in accordance with the national legislation on
the protection of laboratory animals, and the study planswere
approved by the local committee for animal research ethics.
Groups of 3-4 mice were used per data point. Biodistribution
studies were performed on female immunocompetent NMRI
mice (weight: 30 ± 2 g), female Balb/c nu/nu (inoculated
10 million PC-3 cells/mouse 21 days before the experiment,
weight 17 ± 2 g), and male inbred immunodeficient NOD-
SCID mice (5 million PC-3 cells/mouse, 35 days before the
experiment, 31 ± 2 g).
2.4. Biodistribution and In Vivo Binding Specificity in NMRI
Mice. FemaleNMRImicewere injectedwith 45 pmol (100𝜇L
in PBS) 57Co-NOTA-PEG2-RM26 into the tail vein. The
injected radioactivity was adjusted to 30 kBq per animal.
To test the in vivo binding specificity of 57Co-NOTA-
PEG2-RM26 to murine GRPRs, one group of animals was
intravenously coinjected with 20 nmol of unlabeled peptide.
The mice were euthanized at 30min pi by intraperitoneal
injection of Ketalar-Rompun solution (10mg/mLKetalar and
1mg/mLRompun; 20𝜇L/g bodyweight). Blood samples were
collected by cardiac puncture. Lung, liver, spleen, pancreas,
stomach, small intestines, kidneys, muscle, bone, and the rest
of intestines with their content were collected. The organs
were weighed and their radioactivity content was measured
in a gamma-counter.The data were corrected for background
radiation. The organ uptake values were expressed as a
percentage of injected dose per gram of tissue (% ID/g),
except for the gastrointestinal tract and the remaining carcass,
which were calculated as % ID per whole sample.
2.5. Biodistribution and In Vivo Binding Specificity in PC-
3 Xenografted Mice. Tumor targeting specificity and biodis-
tribution over time were studied on PC-3 xenografted
female Balb/c nu/nu and male NOD-SCID mice, respec-
tively. For the in vivo binding specificity experiment, the
animals were injected with 45 pmol (20 kBq, 100 𝜇L in 0.1%
BSA in PBS) of 57Co-NOTA-PEG2-RM26. An additional
group of animals was coinjected with an excess of non-
labeled peptide (20 nmol). The mice were sacrificed at 3 h
pi by intraperitoneal injection of Ketalar-Rompun solution
(10mg/mL Ketalar and 1mg/mL Rompun; 20𝜇L/g body
weight). Other groups of mice were intravenously injected
into the tail vein with 16.8 ± 3.6 pmol of 57Co-NOTA-PEG2-
RM26 (55 ±12 kBq, 100 𝜇L in 0.1% BSA in PBS). The mice
were euthanized at 3 and 24 h pi by cervical dislocation.
Tumors, blood, and other organs of interest were collected,
weighed, andmeasured on radioactivity content in a gamma-
counter. The data were corrected for background radiation.
The organ uptake values were expressed as a percentage of
injected dose per gram of tissue (% ID/g), except for the
gastrointestinal tract and the remaining carcass, which were
calculated as % ID per whole sample.
2.6. SPECT/CT Imaging Using 57Co-NOTA-PEG2-RM26.
Mice bearing PC-3 xenografts were intravenously injected
with 100 pmol of 57Co-NOTA-PEG2-RM26 (600 kBq). The
animals were euthanized by CO2 asphyxiation 3 h and 24 h
pi immediately before being placed in the camera. Whole
body SPECT/CT scans were performed using the Triumph
Trimodality System (TriFoil Imaging, Inc., Northridge, CA,
USA) at the following parameters: CT: 80mm field of view
(FOV), 1.48 magnification, 1 projection, and 512 frames;
SPECT: 80mm FOV and 75A10 collimators (5 pinholes). CT
raw files were reconstructed by Filter Back Projection (FBP).
SPECT raw data were reconstructed using an ordered Subset
Expectation Maximization (OSEM) iterative reconstruction
algorithm. SPECT and CT data were analyzed using PMOD
v3.508 (PMOD Technologies Ltd., Zurich, Switzerland) and
were presented as maximum intensity projections (MIPs).
2.7. PET/CT Imaging Using 55Co-NOTA-PEG2-RM26. Male
NOD-SCID mice bearing PC-3 xenografts were intra-
venously injected with 0.18 nmol (approx. 3MBq) of 55Co-
NOTA-PEG2-RM26 in the tail vein. At 3 h pi the animals (𝑛 =
3) were anesthetized using isoflurane and PET/CT scanned
using the Siemens Inveon Multimodality preclinical scanner
(Siemens Healthcare, Knoxville, USA). At 24 h pi the animals
were euthanized by intraperitoneal injection of pentobarbital
and PET/CT scanned again. CT parameters were 2 bed
positions, 360 projections in 360 degrees’ rotation, and bin
4. The PET acquisition times of the static scans were 900 s
and 1800 s at 3 h and 24 pi, respectively. The PET data were
attenuation corrected using the coregistered CT scan and
the sinograms were reconstructed using the OSEM3D-MAP
reconstruction algorithm (4 OSEM3D iterations, 16 MAP
subsets, and 18 MAP iterations, target resolution 0.8mm).
PET and CT data were analyzed using Inveon Research
Workplace (Siemens Healthcare) and presented as MIPs
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Figure 1: Schematic overview of the structure of 55/57Co-NOTA-PEG2-RM26.
adjusted to display a color scale from 0 to the maximum
tumor uptake value.
3. Results and Discussion
Prostate cancer is a complex disease with a heterogeneous
growth pattern where some patients may not require active
treatment, while others need drastic intervention. In view
of this biologic and clinical heterogeneity, it is imperative to
distinguish between rapidly and slowly progressing disease
and to accurately determine the stage of PCa in order to pre-
scribe appropriate treatments. Molecular imaging of GRPR
expression can contribute substantially in the initial diagnosis
and staging of PCa bynoninvasively assessing the lymphnode
involvement and other metastases and distinguishing low-
from high-risk disease. However, imaging of low abdominal
lymph node involvement in PCa is challenging and requires
the highest possible sensitivity.
In a recent study we have evaluated the effect of
macrocyclic chelators on the biodistribution and target-
ing properties of 111In-labeled bombesin antagonist RM26
(111In-X-PEG2-RM26 (X = NOTA, NODAGA, DOTA, and
DOTAGA)) [13]. In addition to the main conclusions related
to aspects that underlie the influence of radionuclide-chelator
complexes, the study also highlighted the crucial role of
radionuclide half-life in high sensitivity molecular imaging
and pointed that next day imaging may be preferable due
to higher contrast. In this regard, all conjugates evaluated
in that study demonstrated significantly higher tumor-to-
organ ratios at 24 h pi compared to 4 h pi. Therefore, we have
investigated in this project a new probe, 55Co-NOTA-PEG2-
RM26, for next day PET imaging of GRPR expression in PCa
that would combine the advantages of later imaging with the
high sensitivity and quantitative accuracy of PET.
Labeling of NOTA-PEG2-RM26 with radiocobalt was
performed in acidic conditions that should prevent oxida-
tion of Co(II) by atmospheric oxygen to Co(III) that is
common in alkaline solutions [21]. Labeling was successful,
with yields exceeding 99% for 57Co and 98% for 55Co.
57Co-NOTA-PEG2-RM26 (Figure 1) was characterized by
excellent stability (Table 1) and retained the capacity to bind
specifically to GRPR-expressing PC-3 cells (Figure 2(a)).
Binding of 57Co-NOTA-PEG2-RM26 to GRPR-expressing
PC-3 cells was significantly (𝑝 < 1.1 × 10−8) reduced when
Table 1: Labeling and stability of 55/57Co-NOTA-PEG2-RM26.
55/57Co-NOTA-PEG2-RM26
Labeling yield for 57Co 99.8 ± 0.2%
Labeling yield for 55Co 98.6%
Release in the presence of excess EDTA∗ 0.7 ± 0.2%
Release in PBS∗ 0.07 ± 0.11%
∗Stability of 57Co-NOTA-PEG2-RM26 was checked after 1 h incubation
at room temperature in the presence of 1000x excess of EDTA. Data are
presented as average ± standard deviation.
presaturating the receptorswith a largemolar excess of nonla-
beled peptide, indicating that binding of 57Co-NOTA-PEG2-
RM26 is receptor-dependent. The binding pattern of 57Co-
NOTA-PEG2-RM26 was characterized by a rapid increase
in total cell-associated radioactivity within the first hour of
incubation, followed by a slower increase until the 24 h time
point (Figure 2(b)). An interesting find was the very low
internalized fraction that reached only 12% of cell-associated
radioactivity after 24 h incubation (Figure 2(b)). Although a
low internalized fraction is expected from antagonists, the
internalized fraction for 57Co-labeled NOTA-PEG2-RM26
was threefold lower compared to the same radioconjugate
labeled with 111In [7, 13]. This might reflect lower residualiz-
ing properties of cobalt-NOTA containing radiocatabolites.
The binding properties of the peptide loaded with cobalt
and, for comparison, indium were evaluated in a competitive
binding assay using 125I-Tyr4-BBN as displacement radioli-
gand (Figure 3). While both IC50 values were in the low
nanomolar range, the cobalt-loaded analog natCo-NOTA-
PEG2-RM26 had two fold higher IC50 values (5.5 ± 0.4 nM)
compared to the natIn-loaded counterpart (2.5 ± 0.1 nM).
These findings are in good agreement with previous results
obtained for bombesin and somatostatin analogs, confirming
that the net charge of the N-terminus of the conjugate has
a strong impact on the binding affinity [12, 13, 22, 23]. In
this case, the positive N-terminus charge of indium-NOTA
complex resulted in higher affinity, while a neutral charge
(cobalt-NOTA complex) decreased the binding affinity. Real-
time measurements of 57Co-NOTA-PEG2-RM26 binding
affinity to GRPR-expressing PC-3 cells revealed𝐾𝐷 values in
the low picomolar range (22 ± 10 pM) with a rapid binding
(association rate of 8.3 × 104 ± 8.7 × 103 1/M × sec) and slow
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Figure 2: (a) In vitro specificity test of 57Co-NOTA-PEG2-RM26 binding to GRPR on PC-3 (human prostate cancer) cells. Presaturation of
receptors with unlabeled NOTA-PEG2-RM26 caused significant (𝑝 < 0.05) reduction of cell-bound
57Co-NOTA-PEG2-RM26 radioactivity.
(b) Binding and internalization of 57Co-NOTA-PEG2-RM26 at 37
∘C by PC-3 cells. Data are normalized to a maximum cell-bound
radioactivity and presented as average value from 3 cell dishes ± SD. Not all error bars are visible due to the small standard deviations.
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Figure 3: (a) Inhibition of 125I-Tyr4-BBN binding to PC-3 cells with natCo-NOTA-PEG2-RM26 and
natIn-NOTA-PEG2-RM26. Data are
presented asmean values of three dishes± SD. (b) LigandTracer sensorgram and fitted binding curve of 57Co-NOTA-PEG2-RM26 interaction
with GRPR-expressing PC-3 cells at room temperature. Uptake curves were recorded at 0.33 and 6 nM. The data were fitted to a one-to-one
interaction model.
dissociation (dissociation rate of 1.8× 10−6 ± 8.0× 10−7 1/sec).
One important advantage of using real-timemeasurements is
the ability to detect the time to equilibrium, which eliminates
the risk of premature interruption of incubation in other
assays. In such a way the intrinsic limitation of the end-
point in vitro assays to study high affinity conjugates (𝐾𝐷
determination in saturation assay, IC50 determination in
inhibition assay) is avoided. In the end-point assays the
values of high affinity conjugates (in low picomolar range) are
underestimated because of the extremely long time required
to reach equilibrium [24]. It should be noted that high
affinity binding is amajor precondition when aiming for high
contrast next day imaging.
The biodistribution of 57Co-NOTA-PEG2-RM26 in
female NMRI mice was characterized by rapid clearance
from blood and normal tissues already at 30min pi
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Figure 5: (a) Biodistribution of 57Co-NOTA- PEG2-RM26 in male NOD-SCID mice bearing PC-3 xenografts at 3 and 24 h pi (total injected
mass of 16.8 ± 3.6 pmol). (b) Tumor-to-organ ratios of 57Co-NOTA- PEG2-RM26 in NOD-SCID mice with subcutaneous PC-3 xenografts.
Data are presented as an average value and standard deviation for three mice.
(Figure 4(a)). The clearance was predominantly renal with
a low kidney retention (6 ± 2% ID/g) and low liver uptake
(0.65 ± 0.05% ID/g). Receptor-positive abdominal organs
(pancreas, small intestine, and stomach) showed high
uptake. In these organs, the accumulated radioactivity was
significantly lower in the group of mice coinjected with
excess amount of unlabeled peptide indicating specific
uptake of 57Co-NOTA-PEG2-RM26. These results were
further confirmed in female Balb/c nu/nu mice bearing
subcutaneous PC-3 tumors at 3 h pi where the tumor uptake
and the uptake in GRPR-expressing organs were inhibited
by coinjection of an excess amount of unlabeled peptide
(Figure 4(b)). The accumulation of radioactivity in normal
organs and excretory organs was not significantly different
upon blocking.
Data concerning the biodistribution of 57Co-NOTA-
PEG2-RM26 over time in PC-3 xenografted mice are pre-
sented in Figure 5. The overall biodistribution pattern of the
cobalt-labeled peptide and the tumor uptake were in good
agreement with the data published for this peptide labeled
with indium-111, gallium-68, and fluorine-18 via aluminum
fluoride [7, 8, 12, 13]. A surprising finding of this study
was the significantly faster whole body and blood clearance
of 57Co-NOTA-PEG2-RM26 compared to the previously
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Table 2: Long-lived positron-emitting radiometals. Data are taken from [10].
Nuclide (half-life) Mode of decay 𝐸max (keV) Principal photon emissions, keV (abundance in %)
55Co (17.5 h) 𝛽
+ 76%
EC 24% 1498 477 (20.2%), 931 (75%), 1317 (7.1%), 1408 (16.9%)
64Cu (12.7 h)
𝛽+ 18
𝛽− 37%
EC 24%
653 1346 (0.5%)
86Y (14.7 h) 𝛽
+ 33%
EC 67% 3141
443 (16.9%), 628 (32.6%), 646 (9.2%), 703 (15.4%), 778 (22.4%), 1077 (82.5%), 1153
(30.5%), 1854 (17.2%), 1920 (20.8%)
(a) (b)
Figure 6: Coronal MIP preclinical PET/CT images showing tracer distribution in PC-3 xenografted NOD-SCID mice. The animals were
injected with 0.18 nmol of 55Co-NOTA-PEG2-RM26 (approx. 3MBq) and scanned at (a) 3 h and (b) 24 h pi.The tumor is shown by the arrow.
evaluated 68Ga and 111In-labeled NOTA-PEG2-RM26 [7].
In this regard, at the 3 h time point the blood levels of
radioactivity for 57Co-labeled NOTA-PEG2-RM26 were 2-
fold lower than 111In- and 6-fold lower compared to 68Ga-
labeled analogs. Different clearance rates from circulation
for peptides and proteins labeled with different radiometals
using the same chelator are a known phenomenon [25–
27]. This could be due to different coordination geometries
that could affect the binding to blood proteins, therefore
modulating the excretion rate. The excretion of radioactivity
was predominantly through the kidneys, as the radioactivity
uptake in both the liver and gastrointestinal tract was low at
all time points.
The rapid clearance of radioactivity from blood (0.05 ±
0.02% ID/g) and normal organs resulted in high tumor-to-
organ ratios already at 3 h pi (Figure 5(b)). Remarkably, the
tumor uptake exceeded the uptake in all other organs andwas
7-fold higher than pancreas, the organ with the second high-
est uptake at 3 h pi. This discrepancy in retention of radioac-
tivity between xenografts and receptor-positive organs was
previously reported for 68Ga and 111In-labeled NOTA-PEG2-
RM26 [7] as well as other bombesin analogs [28–30] and
could be attributed to interspecies differences betweenmouse
and human GRPR or to receptor density in tissues. The rapid
radioactivity washout from normal and receptor-positive
organs together with a higher retention of the radioconjugate
in tumors resulted in a further increase of tumor-to-organ
ratios over time. Therefore, exceptionally high tumor-to-
blood, tumor-to-pancreas, tumor-to-stomach, and tumor-to-
kidney ratios were achieved at 24 h pi. For comparison, for
radiocobalt-labeled bombesin agonist AMBA the tumor-to-
blood ratio at this time point was 7-fold lower, tumor-to-
kidney 9-fold lower, tumor-to-liver 1.5-fold lower, tumor-to-
colon 80-fold lower, and tumor-to pancreas 300-fold lower
[14].
The high potential of radiocobalt-labeled NOTA-PEG2-
RM26 for imaging of GRPR-expressing tumors was con-
firmed by 𝜇PET/CT images using 55Co-NOTA-PEG2-RM26
(Figure 6). Similar to the biodistribution results, the predom-
inant radioactivity uptake was seen in tumors. The kidney
and urinary bladder uptake could also be visualized at both
3 h and 24 h pi due to the predominant renal excretion of
the radiotracer. The SPECT/CT and 𝜇PET/CT MIP images
together with the biodistribution results suggest 24 h pi as the
optimal time point for image acquisition.
Cobalt-55 was used in ionic form in several clinical
studies as tracer that may reflect calcium (Ca) influx [31–33].
This PET radioisotope has favorable properties for noninva-
sive imaging: relatively long half-life (17.5 h), production at
low-energy cyclotrons available in most PET facilities, and
the highest positron abundancy among positron-emitting
radiometals with comparable half-life (Table 2). It can be
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(a) (b)
Figure 7: Coronal MIP preclinical SPECT/CT images showing tracer distribution in PC-3 xenografted BALB/C nu/nu mice. The animals
used for SPECT camera imaging were injected with 45 pmol of 57Co-NOTA- PEG2-RM26 (300 kBq) and euthanized at (a) 3 h and (b) 24 h
pi.
produced by low-energy medical cyclotrons available in
most PET facilities and due to the long half-life it can
be distributed to distant sites. The production costs of a
batch of cobalt-55 should be in the same range as a batch
of copper-64. However, until recently radiocobalt was not
used for labeling of peptides and proteins for molecular
imaging due to undeveloped labeling chemistry. Within the
last years several groups reported labeling with radiocobalt
isotopes of scaffold proteins affibody molecules DOTA-
ZHER2 [27] andDOTA-ZHER1 [34], GRPR-agonistic BNanalog
NOTA-AMBA [14], and somatostatin analogs DOTATATE,
DOTATOC, and DOTANOC [18, 19]. Both tetra- and tri-
aza-chelators demonstrated stable coordination of divalent
cobalt. For preclinical development cobalt-55 is rather expen-
sive. Cobalt-57 has half-life of 271.6 days, emits photons
with convenient energy (122 keV (86%), 136 keV (10%)), and
can be used for preclinical experiments in the same way as
iodine-125 is used for development of radiotracers instead
of iodine-124 (PET isotope), iodine-123 (SPECT isotope),
and iodine-131 (therapeutic isotope). To prove this, we per-
formed 𝜇SPECT/CT imaging of GRPR-expressing tumors
using 57Co-NOTA-PEG2-RM26 at 3 h and 24 h pi (Figure 7).
Similar to the 𝜇PET/CT images and the biodistribution
results, the predominant radioactivity uptake was seen in
tumors. Traces of radioactivity could also be observed in the
kidneys at 3 h pi. At the 24 h pi, due to the fast clearance of
radioactivity from normal organs, only the tumor could be
visualized.
4. Conclusions
We have developed a peptide-based targeting agent labeled
with 55Co for next day high contrast PET imaging of GRPR-
expressing tumors.We have also demonstrated that long lived
57Co can be used as a surrogate for 55Co in preclinical studies.
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